Zusammenfassung
Die häufigsten angeborenen hämorrhagischen Diathesen sind Störungen der plasmatischen Gerinnung. Ursachen sind
-
die quantitative Verminderung eines oder mehrerer Gerinnungsfaktoren,
-
verminderte oder fehlende Aktivierbarkeit eines oder mehrerer Gerinnungsfaktoren aufgrund eines qualitativen Defekts,
-
die Präsenz eines Inhibitors, der ihre Aktivierung blockiert.
Die häufigsten Störungen sind die Hämophilie A und B und das von-Willebrand-Syndrom. Selten sind vererbte Mangelzustände der Gerinnungsfaktoren I, II, V, VII, X, XI, XII und XIII. Eine kausale Therapie ist bisher beim Menschen nicht möglich. Das quantitative Ausmaß der Defekte bestimmt die Blutungsneigung, wobei die hämostatische Mindestaktivität für jeden einzelnen Gerinnungsfaktor unterschiedlich ist.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Aledort LM and the International Study Group (1992/93) Orthopedic outcome study. Vorgetragen auf den Sitzungen des SSC der ISTH, München 1992 und New York 1993
Allain J-P (1976) Dosage requirements for substitution therapy in hemophiliacs; general principles. Scand H Haematol 1090; 24 (Suppl 35):29–32
Allain JP, Frommel D (1976) Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 47:973–982
Anson DS, Choo KH, Rees DJG, et al. (1984) The gene structure of human antihaemophilic factor IX. EMBO J 3:1053–1060
Antonarakis SE, Rossiter JP, Young, et al. (1995) Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 86:2206–2212
Astermark J, Berntorp E, White GC, et al. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 7:267–272
Astermark J, Oldenburg J, Pavlova A, et al. (2006) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with haemophilia A. Blood 107:3167–3172
Astermark J, Oldenburg J, Carlson J, et al. (2006) Polymorphisms in the TNFA gene and the risk of inhibitor development in patiennts with haemophilia A. Blood 108:3739–3745
Astermark J, Wang X, Oldenburg J (2007) Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe haemophilia A. J Thromb Haemost 5:263–265
Bardin JM, Sultan Y (1990) Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery. Transfusion 30:441–443
Berkowitz SD, Ruggeri ZM (1994) The management of von Willebrand Disease. Biomed Prog 7:5–10
Berntorp E (1994) Die Auswirkungen einer Subsitutionstherapie auf das Immunsystem von Blutern. Hämostaseologie 14:74–80
Brackmann H-H (1984) Induced immunotolerance in factor VIII inhibitor patients. In: Hoyer LD (ed) Factor VIII inhibitors. Liss, New York, pp 181–195
Brackmann HH, Lenk H, Scharrer J, et al. (1999) German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 5:203–206
Brettler DB, Levine PH (1994) Clinical Manifestations and therapy of inherited coagulation factor deficiencies. In: Colman RW, Hirsh J, Marder VJ, Salzmann EW (eds) Hemostasis and thrombosis, 3rd edn. Lippincott, Philadelphia, pp 169–183
Chalmers EA, Brown SA, Keeling D, et al. (2007) Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 13:149–155
Collins P, Budde U, Rand JH, et al. (2008) Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia 14:49–55
Collins PW, Mathias M, Hanley J, et al. (2009) Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. J Thromb Haemost 7:787–794
Delannoy A, Saillez AC (1988) High-dose intravenous gamma globulin for acquired vWd. Br J Haematol 70:387
Dimichelle DM, Hoots WK, Pipe SW, et al. (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia 13:1–22
European Study Group of Factor VIII Antibody (1979) Development of factor VIII antibody in haemophilic monocygotic twins. Scand J Haematol 23:64–68
Ewing NP, Sanders NL, Dietrich SL, et al. (1988) Induction of immune tolerance to factor VIII in hemophiliac with inhibitors. JAMA 259:65–68
Gawryl MS, Hoyer LW (1982) Inactivation of factor VIII procoagulant activity by two different types of human antibodies. Blood 60:1103
Gitschier J, Wood WI, Goralka TM, et al. (1984) Characterization of the human factor VIII gene. Nature (London) 312:326
Goldsmith JC and the Recombinante Study Group (1991) Clinical trial of Recombinate: safety and efficacy of a genetically engineered antihemophilic factor in previously treated patients. Blood 78 (Suppl 1):64a
Goudemand J, Rothschild C, Demiguel V, et al. (2006) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. Blood 107:46–51
Gouw SC, van den Berg HM, le CS, et al. (2007) Treatment characteristics and the risk of inhibitor develoment: a multi-center cohort study among previously untretaed patients with severe haemophilia A. J Thromb Haemost 5:1383–1390
Gouw SC, van der Bom JG, van den Berg M, et al. (2007) Treatmentrelated risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 109:4648–4654
Gralnick HR (1991) Von Willebrand’s Disease. In: Ratnoff OD, Forbes ChD (eds) Disorders of Hemostasis. Saunders, Philadelphia, pp 203–244
Hedner U (2003) Recombinant factor VII a (Novo Seven) as a hemostatic agent. Dis Mon 49:39–48
Hellmann L, Smedsröd B, Sandberg H, Pettersson U (1989) Secretion of coagulant factor VIII activity and antigen by in vitro cultivated rat liver sinusoidal endothelial cells. Br J Haematol 73:348–355
Hoeben RC, Fallaux FJ, Van Tilburg NH, Cramer SJ, Van Ormondt H, Briët E, Van der Eb AJ (1993) Toward gene therapy for Hemophilia A: long-term persistence of factor VIII-Secreting Fibroblasts after transplantation into immunodeficient mice. Human gene therapy 4:179–186
Hunault M, Bauer KA (2000) Recombinant factor VII a for the treatment of congenital factor VII deficiency. Semin Thromb Hemost 26:401–405
Jaffe EA, Hoyer LW, Nachmann RL (1974) Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 71:1906–1909
Kernoff PBA, Thomas ND, Lilley PA, Matthews KB, Goldmann E, Tuddenham GD (1984) Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 63:31
Kiesewetter H, Spannagl M (2009) Prokoagulatoren. In: Bundesärztekammer (Hrsg) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. Aufl. Deutscher Ärzte-Verlag, S 131–167
Köhler M, Hellstern P, Miyashita C, et al. (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemostas 55:108–111
Köhler M, Seifried E, Hellstern P, Pindur G, Leipnitz G, Mörsdorf S, Fasco F, Wenzel E (1988) In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients – the influence of reagents and standards. Blut 57:341–345
Köhler M, Hellstern P, Tarrasch H, et al. (1989) Subcutaneous injection of esmopressin (DDAVP): Evaluation of a new, more concentrated preparation. Haemostasis 1:38–44
Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B (1994) Haemate P® in Children with von Willebrand’s Disease. Haemostasis 1994:304– 310
Kreuz W, Becker S, Lenz E, et al. (1995) Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance of factor VIII. Sem Thromb Hemost 21:382–389
Kreuz W, Auerswald G, Ehrenforth S, et al. (1996) Immuntoleranz bei Kindern mit Hemmkörperhämophilie. In: Scharrer J, Schramm W (Hrsg) 25. Hämophilie-Symposium 1994. Springer, Berlin Heidelberg New York, S 67–80
Landbeck G (1987) HIV-Infektion, AIDS-Manifestation und Todesursachen Hämophiler der Bundesrepublik Deutschland. Elipse 1987:156
Lechner K, Fasching I, Niessner H, Novotny C (1983) Current situation of home care in Austria. In: Abe T (ed) Proc 3rd Int Symp H T. Kyoritsu Printings, Tokyo, p 105
Lethagen S, Ragnarson-Tennvall G (1993) Self-treatment with desmopressin intranasal spray in patients with bleeding disorders. Effect of bleeding symptoms and socio-economic factors. Ann Hematol 66:257–260
Lethagen S, Harris AS, Sjörin E, Nilsson IM (1987) Intranasal and intravenous administration of desmopressin. Effect of VIII/vWF, pharmacokinetics and reproducibility. Thrombos Haemostas 58:1033–1036
Liu H-W, Ofosu FA, Chang PL (1993) Expression of Human IX by microencapsulated recombinant fibroblasts. Human Gene Ther 4:291–301
Logan LJ (1992) Treatment of von Willebrand’s Disease. In: Penne JA, Hassouna HJ (eds) Hematology/oncology clinics in North America, coagulation disorders I. Saunders, Philadelphia, pp 1079–1094
Lusher Ju (2002) First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Sem Thromb Hemost 28:273–276
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate Previously Untreated Patients Study Group (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy and development of inhibitors. N Engl J Med 328:453–459
Mannucci PM (1993) Clinical evaluation of viral safety coagulation factor VIII and IX concentrates. Vox Sang 64:197–203
Mannucci PM (1995) Risk of inhibitor development after intermediate purity coagulation factor concentrates: Is it truly low? Thrombos Haemost 74:997
Mannucci PM, Lusher JM (1989) Desmopressin and thrombosis. Lancet II:675–676
Mannucci PM, Lombardi R, Bader R, et al. (1984) Studies of the pathophysiology of acquired vWD in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 64:614
Martinowitz U, Luboshitz J, Bashari D, et al. (2009) Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia A. Haemophilia 15:676–685
Mauser-Bunschoten EP, Nilsson IM, Kasper CK (1991) Immune tolerance, a 1990 approach: In: Lusher JM, Kessler CM (eds) Hemophilia and Kapitel 25 • Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand-Syndrom von Willebrand’s Disease in the 1960s. Elsevier, Amsterdam New York, pp 265–269
McMillan CW, Shaprio SS, Whitehurst D, et al. (1988) The natural history of factor VIII : C inhibitors in patients with hemophilia A. A national cooperative study. II Observations on the initial development of factor VIII: C inhibitors. Blood 71:344
Michiels JJ, Budde U, van der Planken M, et al. (2001) Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Clin Haematol 14:401–436
Miesbach W (2008) Laboratory diagnosis and clinical manifestations of patients with dysfibrinogenemia. J Lab Med 32:401–405
Miesbach W, Galanakis D, Scharrer I (2009) Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. Blood Coagul Fibrinolysis 20:366–370
Montgomery RR, Coller BS (1994) Von Willebrand Disease. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis. Lippincott, Philadelphia, pp 134–168
Niessner H (1988) von-Willebrand-Syndrom. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York, S 392–403
Nilsson IM (1991) Prophylactic treatment of severe haemophilia in Sweden. R Soc Med Serv, Round Table Ser 25: Factor VIII: purity and prophylaxis, pp 36–40
Nilsson IM, et al. (1994) Hemophilia, Pharmacia Plasma Products (Hrsg Fa. Pharmacia)
Oldenburg J (2001) Mutation profiling in haemophilia A. Thromb Haemost 85:577–579
Oldenburg J, Schwaab R (2001) Molecular biology of coagulation factors. Semin Thromb Hemost 27:313–324
Oldenburg J, Brackmann HH, Schwaab R (2000) Risk factors for inhibitor development in haemophilia A. Haematologica 85:7–14
Pabinger I, Lechner K (1988) Therapie mit plasmatischen Gerinnungsfaktoren. In: Mueller-Eckhardt C (Hrsg) Transfusionsmedizin. Springer, Berlin Heidelberg New York, S 373–381
Pittmann D, Millenson M, Marquette K, et al. (1992) A2 domain of human recombinant-derived F VIII is required for procoagulant activity but not for thrombin cleavage. Blood 79:389–397
Rosendaal FR, Veltkamp I, Smit C, et al. (1989) Mortality and causes of death in Dutch haemophiliacs, 1973–86. Br J Haematol 71:71–76
Rosendaal FR, Smit C, Briet E (1991) Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 62:5–15
Ruggeri ZM, Ware J (1993) Von Willebrand factor. FASEB J 7:308–316
Scharrer I (1994) Rekombinante Faktor-VIII-Konzentrate. Hämostaseologie 14:69–73
Scharrer I, Vigh T, Aygören-Pürsün E (1994) Experience with haemate P in von Willebrand’s disease in adults. Haemostasis 298–303
Schimpf K (1976) Factor VIII dosis in prophylaxis of hemophilia A; a further controlled study. In: Proc 11th Congr World Fed Hemophilia, Kyoto, vol 8. Academia (Tokyo) 8:363–366
Schimpf K (1986) Liver disease in haemophilia. Lancet I:323 u. 572
Schimpf K (1994) Therapie der Hämophilien. Hämostaseologie 14:44–54
Schramm W (1983–1993) Chronologie zu Hämophilie und AIDS, Hamburger Hämophilie-Symposien 1983–1993
Schramm W (1993) Experience with prophylaxis in Germany. Seminars Hematol 30 (Suppl 2):12–15
Schramm W (1994) Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland. Hämostaseologie 1994:81–83
Schramm W (1995) Sustitutionstherapie bei thrombophilen und hämophilen Diathesen. Hämostaseologie 15:210–214
Schramm W, Krebs H (2003) HIV infection and causes of death in patients with hemophilia in Germany (Year 2000/2001 Survey). 32nd Hemophilia Symposium Hamburg 2001. Springer, Berlin Heidelberg, pp 3–12
Schramm W, Oldenburg J (2009) Faktor-VIII-Konzentrate, Faktor-VIII-/von Willebrand-Faktor-Konzentrate, Faktor IX-Konzentrate, aktivierte Prothrombinkomplex-Konzentrate. In: Bundesärztekammer (Hrsg) Querschnitts-Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 4. Aufl. Deutscher Ärzte-Verlag, S 111–130
Schramm W, Scharrer I (2000) Konsensus-Empfehlungen zur Hämophiliebehandlung in Deutschland. GTH-Hämophiliekommission, Update 1999. Hämophilieblätter 34:62–65
Shapiro SS, Hultin M (1975) Acquired inhibitors to the blood coagulation factors. Sem Thromb Hemost 1:336
Shelton Inloes BB, Mannucci PM, Federici AB, Sadler JE (1987) Gene deletions correlate with the development of alloantibodies in VWD. J Clin Invest 79:1459
Silberstein LE, Abrahm J, Shattil SJ (1987) The efficacy of intensive plasma exchange in acquired vWd. Transfusion 27:234
Smith MP, Spence KJ, Waters El, et al. (1999) Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thromb Haemost 81:35–38
Sporn LA, Chavin SI, Marder VJ, Wagner DD (1985) Biosynthesis of on Willebrand protein by human megakaryocytes. J Clin Invest 76:1102–1106
Sultan Y (1995) High pun’ty factor VIII concentrates for the treatment of HIV-positive patients with haemophilia. Blood Coagul Fibrinolysis 6 (Suppl 1):80–81
Tedder RS, Briggs M, Ring C, et al. (1991) Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophilia. Br J Haematol 79:512–515
Uehlinger J, Rose E, Aledort LM, Lemer R (1989) Successful treatment of an acquired vWf antibody by extracorporeal immunoadsorption. N Engl J Med 320:254
Varon D, Martinowitz U (1998) Continuous infusion therapy in haemophilia. Haemophilia 4:431–435
von Auer C, Oldenburg J, von Depka M (2005) Inhibitor development in patients with haemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 1051:498–505
von Willebrand EA (1926) Finska Lakaresallsb Handl 68:87–112
Wion KI, Kelly D, Summerfield JA, et al. (1985) Distribution of factor VIII mRNa and antigen in human liver and other tissues. Nature (London) 317:726–729
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Seifried, E., Müller, M., Miesbach, W., Oldenburg, J. (2010). Angeborene plasmatische Gerinnungsstörungen einschließlich von-Willebrand- Syndrom. In: Kiefel, V., Mueller-Eckhardt, C. (eds) Transfusionsmedizin und Immunhämatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12765-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-12765-6_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12764-9
Online ISBN: 978-3-642-12765-6
eBook Packages: Medicine (German Language)